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Abstract
The aim of the project was to identify clinical and quality of life (QL) factors that together predict survival and response to
chemotherapy in advanced breast cancer. Potential prognostic factors were studied in 187 women with baseline QL data from a
trial of paclitaxel versus doxorubicin as first-line chemotherapy. Demographic and clinical factors studied were age, performance
status, dominant site of disease and preceding disease-free interval (DFI). Factors from the EORTC QLQ-C30 were all function
scales, fatigue, nausea/vomiting, pain, dyspnoea, insomnia, loss of appetite and global QL. The proportional hazards regression
model with stratification for treatment, and the logistic regression model adjusting for treatment arm were used for univariate and
multivariate analyses of survival and response to treatment, respectively. For survival, multiple sites of visceral disease, pain, global
QL and fatigue were significant prognostic factors in the univariate analysis. The final multivariate model predicted poor survival
with multiple sites of visceral disease (P=0.003), DFI 42 years (P=0.026) and pain (P=0.003). For response, age, dyspnoea,
fatigue and global QL were significant predictive factors in the univariate analysis. The final multivariate model for response
selected DFI (P=0.009), multiple sites of visceral disease (P=0.037) and dyspnoea (P=<0.001) using forward selection, but model
instability was indicated by the inclusion of fatigue and emotional function in the final model when backward selection was used. In
addition to known clinical factors, patient-assessed QL variables appear to be prognostic for survival and response to chemother-
apy in women with advanced breast cancer. However, identification of prognostic factors from responses to questionnaires may be
unstable, and their reliability and clinical utility should be tested prospectively. # 2000 Elsevier Science Ltd. All rights reserved.
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1. Introduction
Prognostic factor analyses are used to identify vari-
ables that should be used to stratify patients in the
design and analysis of clinical trials, to assist in the
interpretation of the data generated by such trials, and
to aid in the clinical management of individual cancer
patients. Many demographic and clinical variables have
been identified as prognostic factors for women with
advanced breast cancer, including age, menopausal sta-
tus, hormone receptor status, performance status, sites
of metastases, prior adjuvant chemotherapy and dis-
ease-free interval (DFI). Whilst identification of factors
that are prognostic for survival or predictive of response
to treatment is intended to assist clinicians, such infor-
mation is often dicult to use in practice because of
conflicting results arising from dierences in the design
0959-8049/00/$ - see front matter # 2000 Elsevier Science Ltd. All rights reserved.
PI I : S0959-8049(00 )00144-1
European Journal of Cancer 36 (2000) 1498–1506
www.ejconline.com
* Corresponding author. Tel.: +353-1-2161-284; fax +353-1-2161-
200.
E-mail address: currand@iconirl.com (D. Curran).
and methodology of clinical trials [1] and in the statis-
tical analyses employed [2].
Recently, several exploratory studies have suggested
that quality of life (QL) and other patient-assessed
variables have ‘independent’ prognostic significance,
raising the possibility that they add important prog-
nostic information to that provided by clinical variables.
This finding is potentially important for the design of
studies, particularly those involving palliative therapies.
Studies using linear analogue self-assessment (LASA)
scales [3–5], the Functional Living Index in Cancer
(FLIC) [6,7], the Therapy Impact Questionnaire (TIQ)
[8,9], the Rotterdam Symptom Checklist [10,11] and
other instruments [12,13] have suggested that many QL
variables might have prognostic importance.
The European Organization for Research and
Treatment of Cancer (EORTC) QLQ-C30 quality of
life core questionnaire [14] has also been used to iden-
tify prognostic factors. Coates and colleagues [15] and
Dancey and associates [16] studied large heterogeneous
groups of patients with cancer and entered baseline
QL variables measured using the EORTC QLQ-C30
into multivariate models containing clinical prognostic
factors such as performance status. Good social func-
tion and global QL were associated with a longer sur-
vival in advanced cancer [15]. A good global QL score
was associated with a better prognosis in a mixed
group of cancer patients about to receive their first
course of chemotherapy, but poor emotional function
(score below the mean for the group) also predicted
longer survival [16]. Tannock and associates [17] stud-
ied patients with hormone-resistant prostate cancer,
and found that low pain intensity and good physical
function at baseline were associated with a better
prognosis.
Part of the diculty of interpreting such studies arises
from the self-assessment questionnaires themselves, in
which individual items or subscales may be highly cor-
related. The literature suggests that the results of prog-
nostic factor analyses using variables derived from
questionnaires could be unstable because of high cor-
relation between variables. Coates and colleagues [5]
noted considerable correlation between variables mea-
sured using LASA scales, and observed that minor var-
iations in their correlations may dictate which variables
remain in the final regression model that determines
prognostic factors. Strong correlations have also been
observed between items on the QLQ-C30 [14]. In multi-
ple regression when some or all of the variables are
highly correlated, it is dicult to disentangle their
influences and obtain an estimate of their individual
eects [18]. The statistical handling of this phenomenon,
known as multicollinearity, is complex and will be the
subject of a companion paper investigating its impact
on the interpretation of prognostic factor analyses using
patient-assessed variables.
We report here an exploratory prognostic factor ana-
lysis for response and survival of clinical and QL data
from a randomised phase II/III trial comparing pacli-
taxel and doxorubicin as first-line therapy in women
with advanced breast cancer. No substantial dierence
in survival or response was expected between the treat-
ments, and so measurement of QL was considered par-
ticularly important in this trial. We also considered it
important to study the correlations between items mea-
sured using the QLQ-C30 in order to observe their
influence in determining the variables selected for final
multivariate models.
2. Patients and methods
EORTC trial 10923 was a prospective, randomised
phase II/III crossover study in advanced breast cancer,
in which the ecacy of paclitaxel 200 mg/m2 as a 3-h
infusion every 3 weeks until progression followed by
doxorubicin 75 mg/m2 (maximum seven courses) as an
intravenous (i.v.) bolus every 3 weeks, was compared
with the reverse regimen of doxorubicin followed by
paclitaxel. The trial was approved by the EORTC Pro-
tocol Review Committee and by the ethics committee of
each participating centre, and was conducted in com-
pliance with the Helsinki declaration. All patients gave
informed consent.
2.1. Patients
To be eligible, patients were required to be female
with histologically or cytologically proven incurable
adenocarcinoma of the breast in overt progression, with
uni- or bidimensionally measurable lesion(s) not pre-
viously treated with chemotherapy for advanced dis-
ease. Patients that were pregnant or lactating were
ineligible. Other requirements for eligibility were East-
ern Cooperative Oncology Group (ECOG)/World
Health Organization (WHO) performance status (PS)
42; age 518 years; life expectancy 53 months; and
adequate haematological, renal, hepatic and cardiac
function. Patients were ineligible if they had a past or
current history of any neoplasm other than breast car-
cinoma; relapse from previous adjuvant chemotherapy
within 3 months of its completion or adjuvant chemo-
therapy containing anthracyclines; active serious infec-
tion; or the presence of symptomatic central nervous
system (CNS) metastases.
2.2. Clinical methods
Baseline clinical data included age, performance sta-
tus, dominant site of disease, details of prior therapy
and date of first relapse. Dominant site of disease was
defined according to International Union Against Cancer
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(UICC) criteria [19]. The EORTC quality of life core
questionnaire (QLQ-C30 v. 1.0) was used to assess QL
[14]. The schedule of QL assessments required a baseline
measurement at randomisation (42 weeks before start-
ing treatment), further assessments at the end of the
third, fifth and seventh cycles of chemotherapy for both
first and second-line treatments, and when the patient
went o study for any reason except death. For the
purpose of this report, only baseline questionnaires were
considered.
When the study was designed the Rotterdam Symp-
tom Checklist (RSCL) [20] was already well established,
whereas the EORTC QLQ-C30 had only recently been
validated. Therefore, both instruments were used to
assess QL to try to ensure that any true dierences in
QL between the treatments were detected. Only the
QLQ-C30 was used for the prognostic factor analysis
reported here, in order to limit the number of variables
studied. The QLQ-C30 consists of five function scales:
physical (PF), role (RF), emotional (EF), cognitive (CF)
and social (SF); three symptom scales: fatigue (FA),
nausea/vomiting (NV) and pain (PA); six single-item
scales (dyspnoea (DY), sleep disturbance (SL), appetite
loss (AP), constipation (CO), diarrhoea (DI) and finan-
cial impact of the disease/treatment (FI)), and a global
health status/quality of life (QL) scale. Items were
scored and scales constructed using the recommended
procedures [21]. In order to limit the number of vari-
ables under consideration, three single-item scales (CO,
DI and FI) were not included in the prognostic factor
analysis.
Survival times were measured from the date of ran-
domisation. Survival times of patients who were known
to be alive at the date of last follow-up were censored at
that date.
Tumour response was assessed according to UICC
criteria [19]. Complete remission was defined as the dis-
appearance of all known disease, determined by two
observations not less than 4 weeks apart. Partial
response was defined as a decrease of at least 50% in the
sum of the products of the largest perpendicular diam-
eters of all measurable lesions (determined by two
observations not less than 4 weeks apart) in the case of
bidimensionally measurable disease, or a decrease of at
least 50% of the sum of the largest diameters of all
lesions for unidimensionally measurable disease. It was
not necessary for all lesions to have regressed to qualify
for a partial response, but no lesion should have pro-
gressed and no new lesion should have appeared.
2.3. Variables studied
The following factors were studied: age, performance
status (PS), dominant site of disease, disease-free inter-
val and QLQ-C30 variables. To minimise bias in selec-
tion, variables were dichotomised at the median where
possible. PS was dichotomised at score 0 versus scores 1
and 2 combined, because only 8% patients had PS=2 at
baseline. Disease-free interval (DFI) was grouped into
newly diagnosed patients with advanced disease
(DFI=0), DFI 42 years and DFI >2 years.
For variables measured using the QLQ-C30, raw
scores were transformed to a linear scale ranging from 0
to 100, with higher scores representing a higher level of
functioning or a higher level of symptoms [21]. In the
case of missing items within a scale, the scale score was
calculated using only those for which values were avail-
able, provided at least half of the items in the scale were
completed. All QL variables except cognitive function
(CF) were subsequently dichotomised at the median to
yield ‘good’ and ‘poor’ scores. CF was dichotomised at
a score of 70 because the median score was 83, and all
scores at or below this value cannot necessarily be
classed as ‘poor’ cognitive function on a scale of zero to
100.
2.4. Statistical considerations
Randomisation was performed using the minimisa-
tion technique [22]. The primary endpoint of the trial
was progression-free survival. QL, response to treat-
ment and overall survival were secondary endpoints.
Survival curves and probabilities were estimated using
the Kaplan–Meier technique [23]. The Cox proportional
hazards regression model with stratification for treat-
ment arm was used for both univariate and multivariate
analyses of survival. The logistic regression model with
treatment arm included in the model was used for both
univariate and multivariate analyses of response.
Clinical factors were entered first to build the final
clinical models for survival and response, and QLQ-C30
variables were then added. A step-up (forward) variable
selection procedure was used to identify QL variables
that contributed additional prognostic information to
the multivariate models for survival and response. For
comparative purposes multivariate models using step-
down (backward) elimination procedures were also fitted.
For the survival prognostic factor analysis the pro-
portionality assumption was checked for each of the
variables under study by testing the dependency of their
hazard ratio over time [24]. The importance of a prog-
nostic factor was assessed using the P value of the Wald
w2 statistic, the hazard ratio and the odds ratio (risk in a
given category compared with the reference one) and its
95% confidence interval for survival and response,
respectively.
Spearman rank correlation (rs) was used to investigate
relationships between QLQ-C30 variables. Data analy-
sis was performed using Statistical Analysis Software
(SAS) [25]. A 5% level of significance was used for
clinical variables, and a 1% level of significance was
chosen for patient-assessed variables to reduce the risk
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of false-positive results arising from multiple testing. All
significance tests were two-sided.
3. Results
Between September 1993 and April 1996, 331 patients
from 20 institutions were randomised into the study. 15
patients were ineligible on clinical grounds. A further 22
patients were not eligible for the QL analysis. 187 of 294
eligible patients completed baseline QL evaluations,
giving a compliance rate of 64%. Further details are
provided in our companion paper in this issue of the
European Journal of Cancer (pp. 1488–1497).
Characteristics of all eligible patients in the trial are
reported elsewhere [26]. Characteristics of 187 eligible
patients with baseline QLQ-C30 questionnaires are
shown in Table 1. Univariate analyses were performed
on data from these 187 patients, but 10 without complete
information on all QL variables were excluded from the
multivariate analyses, leaving 177 patients for whom
complete information was available on all variables for
these analyses. For the clinical prognostic factors of age,
performance status, disease-free interval and dominant
site of disease, no significant dierence in the distribution
of these factors was detected between eligible patients
included and those excluded from the QL analysis.
The median interval between initial diagnosis and
randomisation in the trial was 4.1 years. The median
interval between first relapse and randomisation was 7
months. At the time of analysis, 154/187 (82%) deaths
had been reported, with a median survival of 1.4 years.
Median follow-up was 3.6 years. In the paclitaxel arm
there were 80/94 (85%) deaths and in the doxorubicin
arm 74/93 (80%) for a median survival of 1.3 and 1.5
years, respectively. Response rates were 23/94 (24%) for
paclitaxel and 38/93 (41%) for doxorubicin.
3.1. Prognostic factors for survival
3.1.1. Univariate analysis for survival
Table 2 lists the results of the univariate survival
analysis for each of the variables under study. Poor
survival was associated with multiple sites of visceral
disease, pain, poor global QL and fatigue at baseline,
with poor physical function having borderline sig-
nificance. No other variables were significantly pre-
dictive of survival duration. No major violations of the
proportionality assumptions were detected for any of
the variables studied.
3.1.2. Multivariate analysis for survival
The Cox multivariate model, stratifying by treatment
arm, retained two clinical prognostic factors: multiple
sites of visceral disease (P=0.001) and DFI 42 years
P=0.007). The final model, with QLQ-C30 variables
added to the two significant clinical variables, indicated
that poor survival was associated with multiple sites of
visceral disease (P=0.003), DFI 42 years (P=0.026)
and pain (P=0.003). The backward elimination method
produced the same result. Fig. 1 shows survival accord-
ing to the baseline pain score.
Table 1
Characteristics of eligible patients with baseline QL questionnaires
(n=187)
Paclitaxel n (%) Doxorubicin n (%)
Age (years)
>55 44 (47) 41 (44)
455 50 (53) 52 (56)
WHO performance status
0 40 (43) 36 (39)
1 45 (48) 51 (55)
2 9 (10) 6 (6)
Disease-free interval
=0 (Newly diagnosed) 8 (9) 8 (9)
42 years 40 (43) 28 (30)
>2 years 46 (49) 57 (61)
Prior therapy
Surgery
Mastectomy 37 (39) 47 (51)
Breast conserving 49 (52) 39 (42)
Other (including none) 8 (9) 7 (8)
Radiotherapy 78 (83) 73 (78)
Adjuvant therapy (C, H, I) 44 (47) 57 (61)
H, I for advanced disease 55 (59) 57 (61)
Dominant site of disease
Soft tissue only 4 (4) 9 (10)
Bone  soft tissue 14 (15) 12 (13)
Single visceral 62 (66) 56 (60)
Multiple visceral 14 (15) 16 (17)
C, chemotherapy; H, hormone therapy; I, immunotherapy.
Fig. 1. Duration of survival by QLQ-C30 pain score (420 versus
>20). O, observed number of deaths; n, number of patients; LE20,
420; GT20, >20.
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Table 2
Univariate prognostic factor analysis for survivala
Variable O/n (%) Median survival (years) Hazard ratio (95% confidence interval) P value
WHO PS
0b 62/76 (82) 1.6 1.0
1,2 92/111 (83) 1.3 1.08 (0.78–1.50) 0.648
Age
>55 yearsb 70/85 (82) 1.3 1.0
455 years 84/102 (82) 1.5 1.0 (0.72–1.38) 0.989
Dominant site
Soft tissueb 9/13 (69) 1.9 1.0
Bone 22/26 (85) 1.7 1.39 (0.63–3.07) 0.416
Single visceral 96/118 (81) 1.6 1.45 (0.73–2.90) 0.291
Multiple visceral 27/30 (90) 1.1 2.60 (1.21–5.59) 0.014
Disease-free interval
=0b 14/16 (88) 1.9 1.0
42 years 59/68 (87) 1.1 1.38 (0.77–2.48) 0.279
>2 years 81/103 (79) 1.7 0.92 (0.52–1.63) 0.778
Physical function
>60b 70/89 (79) 1.8 1.0
460 84/98 (86) 1.1 1.52 (1.10–2.10) 0.010
Role function
>50b 68/84 (81) 1.7 1.0
450 86/103 (83) 1.1 1.42 (1.02–1.96) 0.037
Emotional function
>60b 89/108 (82) 1.5 1.0
460 63/76 (83) 1.2 1.02 (0.74–1.42) 0.892
Cognitive function
>70b 108/130 (83) 1.4 1.0
470 44/54 (81) 1.4 0.87 (0.61–1.25) 0.443
Social function
>70b 89/108 (82) 1.5 1.0
470 63/76 (83) 1.1 1.20 (0.87–1.67) 0.272
Global quality of life
>60b 73/94 (78) 1.7 1.0
460 76/87 (87) 0.9 1.61 (1.17–2.24) 0.004
Fatigue
440b 88/110 (80) 1.7 1.0
>40 65/76 (86) 1.0 1.55 (1.12–2.14) 0.009
Nausea/vomiting
=0b 108/130 (83) 1.6 1.0
>0 46/57 (81) 1.0 1.26 (0.89–1.79) 0.202
Pain
420b 73/95 (77) 1.9 1.0
>20 81/92 (88) 1.0 1.64 (1.19–2.27) 0.003
Dyspnoea
=0b 82/100 (82) 1.7 1.0
>0 70/83 (84) 1.1 1.35 (0.98–1.87) 0.070
Insomnia
=0b 58/70 (83) 1.3 1.0
>0 95/115 (83) 1.6 0.91 (0.65–1.27) 0.575
Loss of appetite
=0b 76/95 (80) 1.6 1.0
>0 78/92 (85) 1.1 1.32 (0.95–1.82) 0.095
O, observed number of deaths; n, number of patients.
a 10 patients had missing scores for at least one item.
b Reference category.
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Table 3
Univariate prognostic factor analysis for responsea
Variable R/n (%) Odds ratio (95% confidence interval) P value
WHO PS
0b 27/76 (36) 1
1,2 34/111 (31) 0.77 (0.41–1.45) 0.419
Age
>55 yearsb 34/85 (40) 1
455 years 27/102 (26) 0.52 (0.28–0.97) 0.040
Dominant site
Soft tissueb 5/13 (38) 1
Bone 8/26 (31) 0.85 (0.20–3.50) 0.817
Single visceral 43/118 (36) 1.09 (0.33–3.63) 0.890
Multiple visceral 5/30 (17) 0.35 (0.08–1.56) 0.170
Disease-free interval
=0b 8/16 (50) 1
42 years 14/68 (21) 0.27 (0.08–0.85) 0.025
>2 years 39/103 (38) 0.58 (0.20–1.70) 0.318
Physical function
>60b 37/89 (42) 1
460 24/98 (24) 0.46 (0.24–0.86) 0.016
Role function
>50b 32/84 (38) 1
450 29/103 (28) 0.59 (0.31–1.10) 0.097
Emotional function
>60b 32/108 (30) 1
460 28/76 (37) 1.35 (0.72–2.55) 0.346
Cognitive function
>70b 46/130 (35) 1
470 14/54 (26) 0.63 (0.31–1.29) 0.209
Social function
>70b 41/108 (38) 1
470 19/76 (25) 0.51 (0.26–0.98) 0.045
Global quality of life
>60b 39/94 (41) 1
460 19/87 (22) 0.40 (0.21–0.78) 0.007
Fatigue
440b 44/110 (40) 1
>40 16/76 (21) 0.36 (0.18–0.72) 0.004
Nausea/vomiting
=0b 49/130 (38) 1
>0 12/57 (21) 0.41 (0.19–0.85) 0.018
Pain
420b 34/95 (36) 1
>20 27/92 (29) 0.76 (0.41–1.42) 0.388
Dyspnoea
=0b 42/100 (42) 1
>0 17/83 (20) 0.35 (0.18–0.68) 0.002
Insomnia
=0b 23/70 (33) 1
>0 37/115 (32) 1.01 (0.53–1.91) 0.989
Loss of appetite
=0b 38/95 (40) 1
>0 23/92 (25) 0.49 (0.26–0.92) 0.027
R, observed number of responses; n, number of patients.
a 10 patients had missing scores for at least one item.
b Reference category.
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3.2. Prognostic factors for response
3.2.1. Univariate analysis for response
Poor response was associated with age, DFI 42
years, dyspnoea, fatigue and poor global QL. Poor
physical function and nausea/vomiting at baseline had
borderline significance (Table 3). No other variables
were significantly predictive of response.
3.2.2. Multivariate analysis for response
The logistic regression model for response with treat-
ment arm included in the model retained the same clin-
ical variables as the multivariate survival analysis:
multiple sites of visceral disease (P=0.028) and DFI42
years (P=0.013). The final model including QLQ-C30
variables predicted a poor response with multiple sites
of visceral disease (P=0.037), DFI (P=0.009) and dys-
pnoea (P<0.001). The backward elimination method
included FA and EF in the model: DFI 42 years
(P=0.004), multiple sites of visceral disease (P=0.028),
dyspnoea (P=0.003), good EF (P=0.008) and fatigue
(P=0.004).
3.3. Correlation matrix for QLQ-C30 variables
The variables most strongly associated with pain were
physical, role, social functioning, global health status/
QL (rs<ÿ0.4) and fatigue (rs>0.4); with dyspnoea they
were global health status/QL (rs<ÿ0.4) and fatigue
(rs>0.4) (Table 4). Multicollinearity between items and
scales was evident and many variables were strongly
intercorrelated (jrsj>0.4). Variables with the lowest
correlations were EF, SL, CF, DY and NV.
4. Discussion
This study has shown that QLQ-C30 variables are
significant predictors of survival and response to treat-
ment in advanced breast cancer in addition to clinical
variables. Patient characteristics of those with QL data
available suggest some dierences between treatment
arms but these do not aect the analysis since the sur-
vival model was stratified by treatment arm and the
response model was adjusted for treatment eect. The
significant clinical variables retained in multivariate
models were DFI 42 years and dominant site of dis-
ease. Patients who relapsed within 2 years of diagnosis
may have had more rapidly progressive disease, and
multiple sites of visceral disease are already known to be
associated with a poor outcome. Neither age nor per-
formance status (PS) were retained in the final multi-
variate models for response and survival, although both
are frequently reported to have prognostic importance
and age was just significant for response in our uni-
variate analysis. Our negative finding for PS might be
partly an eect of sample size of the QL data set, as
WHO PS was shown to have borderline significance as a
prognostic factor in the analysis of the full dataset.
Furthermore, eligibility for this study was restricted to
patients with favourable PS, and only 8% had PS=2,
limiting the influence of this variable as a prognostic
factor.
Oestrogen and progesterone receptor (ER and PR)
status of the primary tumour have previously been
identified as significant prognostic factors for survival in
advanced breast cancer [27–29]. However, Blanco and
associates demonstrated that these variables were not
retained in a multivariate model which included DFI,
dominant site of disease and histological grading [29].
The authors concluded that ER status and site of
recurrence were correlated with high concentrations of
ER found in patients with bone metastases, whereas
lower concentrations of ER were related to visceral
recurrence. Information on ER and PR status, and
menopausal status at initial diagnosis were collected in
this study. However, the proportion of patients with
missing data for ER and PR status was 30% and 37%,
respectively. Because of the high proportion of missing
data and owing to the fact that these variables were
reflecting the status of patients at initial diagnosis (note:
the median interval between initial diagnosis and
Table 4
Correlation matrix for EORTC QLQ-C30 function variables, symptoms and global quality of life (Spearman correlation coecients, n=177)
PF RF EF CF SF FA NV PA DY SL AP
Role Function (RF) 0.706
Emotional Function (EF) 0.151 0.196
Cognitive Function (CF) 0.268 0.236 0.361
Social Function (SF) 0.496 0.549 0.322 0.408
Fatigue (FA) ÿ0.657 ÿ0.573 ÿ0.359 ÿ0.464 ÿ0.584
Nausea/Vomiting (NV) ÿ0.353 ÿ0.339 ÿ0.110 ÿ0.151 ÿ0.308 0.421
Pain (PA) ÿ0.495 ÿ0.457 ÿ0.189 ÿ0.294 ÿ0.453 0.511 0.315
Dyspnoea (DY) ÿ0.375 ÿ0.303 ÿ0.288 ÿ0.246 ÿ0.345 0.489 0.294 0.142
Insomnia (SL) ÿ0.044 ÿ0.201 ÿ0.301 ÿ0.116 ÿ0.186 0.203 0.117 0.201 ÿ0.037
Appetite loss (AP) ÿ0.374 ÿ0.344 ÿ0.208 ÿ0.356 ÿ0.361 0.505 0.489 0.318 0.324 0.104
Global health status\QL 0.578 0.523 0.332 0.319 0.674 ÿ0.709 ÿ0.363 ÿ0.535 ÿ0.422 ÿ0.253 ÿ0.413
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randomisation into the trial was 4.1 years) these vari-
ables were not considered in the analysis.
For survival, the univariate analysis showed that
multiple sites of visceral disease, pain, poor global QL
and fatigue were strongly predictive of a poor prog-
nosis, while poor physical function had a borderline
significance. For poor response to treatment, the sig-
nificant univariate predictors were age, DFI 42 yrs
dyspnoea, fatigue and poor global QL, with poor physi-
cal function, as well as nausea/vomiting, again having
borderline significance. Fatigue, poor global QL and
poor physical function are manifestations of far-
advanced disease, so that women with poor scores for
these variables may have been near death and less likely
to respond to treatment. Thus, the important dierences
between the two models were pain for survival, and
dyspnoea for response to treatment.
Pain has been reported to have prognostic significance
in symptomatic hormone-resistant prostate cancer [17]
and after adjusting for clinical factors in advanced non-
small cell lung cancer [30]. The results of the present
study suggest that pain also has prognostic importance
for survival in advanced breast cancer. This is an
important finding, because pain is measurable, poten-
tially allowing clinicians to distinguish those patients for
whom chemotherapy might be more of a burden than
beneficial in future studies. However, just because pain
appears to be an indicator of poor prognosis does not
imply chemotherapy will benefit these patients. More-
over, pain is also amenable to palliative treatment with
radiotherapy, analgesics and a variety of adjuvant mea-
sures, thus allowing patients a number of treatment
options apart from chemotherapy.
Dyspnoea, a symptom that can result directly from
lung pathology, cardiac disease or general manifestations
of chronic systemic disease such as anaemia, appears to
be important for predicting response to treatment in
advanced breast cancer. Ramirez and associates [31]
used the RSCL to identify pretreatment QL variables
that predicted feeling worse or failing treatment in a
consecutive series of women receiving chemotherapy for
advanced breast cancer and found that lacking energy
and dyspnoea, together with liver metastases predicted
treatment failure. This is consistent with our findings
that dyspnoea and multiple sites of visceral disease are
associated with poor response to chemotherapy.
In this study, dierent selection methods for multi-
variate analysis produced dierent results for response,
with backward elimination including fatigue and good
emotional function with dyspnoea as predictors of poor
response. It is dicult to produce a plausible inter-
pretation for the apparent inverse association between
emotional function and response, but we are not the
first to have observed this phenomenon using the QLQ-
C30. Good emotional function has previously been
associated with shorter survival in a general population
of cancer patients receiving chemotherapy [16]. The
consistent findings of these two studies suggest that this
phenomenon warrants further study.
Instability in the model predicting response to treat-
ment arises from the multicollinearity inherently present
between subscales of questionnaires. The influences
determining the selection of variables in multivariate
prognostic factor analyses based on QL questionnaires
have not been investigated systematically and are the
subject of a companion paper in preparation. However,
the correlation matrix and the instability of model
selection for response point to the need for caution
when reporting prognostic factors in this context.
Reports of multivariate prognostic factor analyses
commonly state that statistically significant variables
retained in the model are ‘independently predictive’ of
the outcome of interest (response or survival). This ter-
minology is clearly inaccurate in the case of variables
originating from questionnaires especially when models
select global QL as a significant prognostic factor [15].
The correlation matrix (Table 4) shows that no variable
can be regarded as an ‘independent predictor’ of global
QL since they are all interrelated. It is not surprising,
therefore, that small dierences in their correlations
may dictate which variables remain in the final regres-
sion model. Hauck and Miike [32] have drawn attention
to the danger of overinterpreting the selected variables
as the most important ones in procedures on correlated
sets of variables, and we have observed that variables
from questionnaires are particularly prone to this di-
culty. Our findings support the need identified by Simon
and Altman [2] for prospective confirmatory studies
with specific hypotheses and with particular attention
paid to limiting and controlling problems of multi-
plicity. We chose levels of 0.01 instead of the usual 0.05
to define the statistical significance of patient-assessed
variables in order to reduce the risk of false positive
results from multiple tests.
In conclusion, our findings suggest that QL variables
are important predictors of response to chemotherapy
and survival in advanced breast cancer, and could be
used to identify those patients who are least likely to
benefit from chemotherapy. Specific hypotheses should
be raised to test the predictive value of pain for survival,
and dyspnoea for response to chemotherapy in women
with advanced breast cancer. For clinicians it would
also be important to identify the particular causes of
pain and dyspnoea which influence prognosis.
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